logo
How healthy are boiled eggs?

How healthy are boiled eggs?

USA Today2 days ago

How healthy are boiled eggs?
Show Caption
Hide Caption
How to cook your eggs every way
Whether it's scrambled, over easy or poached, here's how to cook your perfect egg.
If you're after a nutrient-dense breakfast, boiled eggs are a quick and easy way to pack in a few essential nutrients –from antioxidants to B vitamins to choline.
Because you're not adding extra oils or fats into the cooking process, boiled eggs are considered to be one of the healthiest kinds of eggs to eat, says Jeremy O'Neal, a board-certified specialist in obesity and weight management, and licensed dietitian nutritionist specialist in the UI Health Bariatric Surgery Program.
All around, boiled eggs are a low calorie, protein-rich food. What else is there to know about this breakfast staple? We asked the experts to break down all the nutrients found in boiled eggs, how much protein they actually contain and why (for most people) they're a great food to incorporate into an everyday, balanced diet.
How many calories in an egg?
One large boiled egg contains 72 calories, nearly 5 grams of fat and around 1.5 grams of saturated fat, says O'Neal. Eggs, and egg yolks in particular, pack a punch with vitamins and minerals. They're a good source of vitamin A, B vitamins, riboflavin, folate, iron and zinc, he says.
Eggs are also one of the best sources of choline, a mineral that's especially important during pregnancy because it supports the production of acetylcholine, which helps with muscular contractions, he says. Choline has also shown to be important in promoting cognitive function in older adults, says Dr. Amar Dave, a lifestyle medicine specialist with MedStar Health.
How much protein is in an egg?
There's around 6 to 7 grams of protein in one large boiled egg, says O'Neal. Boiled eggs are protein-rich, though you can't rely on them alone to meet all your daily protein needs (which is essential for muscle growth and recovery).
Your protein intake depends on two factors: your body weight, and how much you exercise. For adults, the recommended dietary allowance (RDA) of protein is at least 0.8 grams of protein per kilogram of body weight, according to Harvard Health.
So, if someone weighs 180 pounds, it's recommended they eat around 65 grams of protein a day, says O'Neal. If you're someone who's very active, you're going to need to consume a bit more protein than the average person, somewhere between 1.2 grams to 2 grams of protein per kilogram of body weight. If you're pregnant, it's also recommended your protein intake be higher than average, around 1.1 grams of protein per kilogram of body weight, he says.
What are seed oils? What you need to know about the food group deemed the 'hateful eight'
How often can I eat boiled eggs?
In the context of a balanced diet, for most people, it's perfectly fine to eat two to three boiled eggs per day if you wanted to, says O'Neal.
The Dietary Guidelines for America 2020-2025 recommends eating a wide variety of fruits, vegetables, grains, dairy (or soy as an alternative), healthy oils and protein-rich foods. It's especially important to diversify your protein sources, says Dave. To help meet your protein goals, consider incorporating a mix of lean meats, poultry and eggs. As for plant-based protein sources, he recommends eating foods like steel cut oats, legumes, seeds, lentils and tofu.
Noted: Building muscle requires a higher protein intake. But eating too much protein isn't safe.
Can I eat boiled eggs if I have high cholesterol?
If you have high cholesterol, you may have heard you should either limit your intake of eggs, or avoid eating them entirely. The concern surrounding eggs and cholesterol is mainly to do with eating the egg yolk, where the majority of the dietary cholesterol is concentrated, says O'Neal. One large egg contains approximately 200 milligrams of dietary cholesterol, according to the USDA's Food Data Central.
'Eggs are definitely a larger source of dietary cholesterol, but the association between regular dietary cholesterol consumption, and then high (blood) cholesterol and coronary artery disease, has not been well proven,' says Dave. The relationship between dietary and blood cholesterol has been up for debate for decades, and according to a 2022 review published in Nutrients, recent research still hasn't been able to establish a direct link.
So, if you're someone who's at risk for high cholesterol, it's probably more important to turn your attention to the amount of saturated fat that a boiled egg contains. That's because diets high in saturated fat are strongly correlated with high blood cholesterol, which increases your risk for heart disease and stroke, says Dave. However, even if you have high cholesterol, it still doesn't mean you need to avoid boiled eggs full stop. If you're following a balanced dietary pattern that limits your intake of saturated fat in other areas, like swapping red meats for lean meat, avoiding ultra-processed foods and instead eating lots of vegetables, boiled eggs could (in moderation) could be a nutritious, protein-rich addition to your diet, O'Neal says.
And as always, if you have any dietary concerns, talk to your healthcare provider to discuss an eating pattern that supports your individual health needs.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA Approves Triple Rx for Hypertension
FDA Approves Triple Rx for Hypertension

Medscape

timean hour ago

  • Medscape

FDA Approves Triple Rx for Hypertension

The FDA has approved Widaplik, a triple-drug combination, for the treatment of hypertension in adults. Widaplik combines three drugs — telmisartan, amlodipine, and indapamide — into a single pill that will be available in three doses: 10/1.25/0.625 mg; 20/2.5/1.25 mg, and 40/5/2.5 mg. Intended as initial therapy for patients likely to need multiple medications to control hypertension, the product is expected to be on the market by the end of 2025. The FDA approval for the combination pill was based in part on data from two pivotal phase 3 trials. Those studies found people who took the medication had significantly reduced blood pressure and rates of control over hypertension compared with dual therapy and placebo, according to George Medicines, which makes Widaplik. Widaplik is currently being investigated for the prevention of stroke in patients who have had an intracerebral hemorrhage, the company said. 'Single pill combination antihypertensive therapy has great potential to improve hypertension control in the US and worldwide,' said Paul Whelton, MD, MSc, the how Chwan Health System Endowed Chair in Global Public Health at Tulane University, in New Orleans, in a statement about the approval. 'Most patients with hypertension need multiple therapies to achieve their blood pressure goals. The new dose options available with Widaplik offer a treatment regimen that could benefit a broad range of patients, including those just starting treatment.' Nearly half the adults in the US have hypertension, but only about 1 in 4 have their blood pressure under control. A major risk factor for coronary heart disease, stroke, and heart failure, hypertension is estimated to cause 460,000 deaths in the US each year.

Taletrectinib Approved for NSCLC
Taletrectinib Approved for NSCLC

Medscape

time13 hours ago

  • Medscape

Taletrectinib Approved for NSCLC

The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to

Dermatology Residents Gather for Hands-on Cosmetic Training
Dermatology Residents Gather for Hands-on Cosmetic Training

Yahoo

time18 hours ago

  • Yahoo

Dermatology Residents Gather for Hands-on Cosmetic Training

On May 2-4, the 2025 ASDS Premier Annual Resident Cosmetic Symposium returned to Dallas, Texas, where over 125 dermatology residents immersed themselves in cosmetic procedures, learning from esteemed faculty. 2025 ASDS Resident Symposium in Dallas, Texas Schaumburg, IL, June 11, 2025 (GLOBE NEWSWIRE) -- For the eleventh consecutive year, the American Society for Dermatologic Surgery's (ASDS) sold out with a record 127 dermatology residents and post-residency fellows-in-training receiving $300 scholarships to on cosmetic procedures that are often not thoroughly explored in residency programs. Established in 2015, the Symposium was created to fill a gap in residency training for cosmetic dermatologic procedures. These new physicians are eager to learn from the tenured faculty's clinical insights and engage in interactive teaching elements including: live patient demonstrations, meaningful lectures with case studies, faculty panels with extensive Q&A opportunities, hands-on training and small group breakout discussions. Topics covered gender and ethnic considerations; facial assessments; injectable anatomy demonstration; overviews of lasers, energy-based procedures, injectables, chemical peels, liposuction, fat reduction and muscle toning; and practice management and career paths. As a bonus, attendees received access to on-demand lectures on facial anatomy, cosmeceuticals, hair loss, microneedling and sclerotherapy. Course Directors and Expert Faculty 'I'm thrilled that our 2025 attendees rated this course a 4.8 out of 5, with 99% of attendees agreeing that the content was relevant to their educational needs and presented in a conducive format,' said course Co-Director Thomas Rohrer, MD. '93% felt their attendance improved their competence, and 80% believe their participation will improve their performance — and thereby improving patients' outcomes. These encouraging statistics and raving testimonials demonstrate that the Symposium is a profoundly effective and valuable educational activity for our next generation of dermatologists.' 'This Symposium was a fantastic opportunity for these future leaders to expand their knowledge and skills in areas of cosmetic dermatology that require specific training to ensure optimal outcomes and patient safety,' said Co-Director Susan Weinkle, MD. 'Our wonderful faculty and generous corporate partners made the 2025 course a huge success for our attendees, many of whom have expressed appreciation for the interactive learning format, diverse content and engaging networking opportunities.' ASDS thanks the course directors, Drs. Rohrer and Weinkle, and the 13 expert faculty for their dedication to furthering residents' education: Eric Bernstein, MD, MSE Kimberly Butterwick, MD M. Laurin Council, MD, MBA Sue Ellen Cox, MD DiAnne Davis, MD Rebecca Kazin, MD Kavita Mariwalla, MD Kristel Polder, MD Heidi Prather, MD Jennifer Rullan, MD Brian Zelickson, MD Attendee Testimonials 'I was moved by the generosity of the faculty, not only in the time they committed to organizing the Symposium, but also in their candidness regarding career and life advice. Their commitment to serving as advisors and showcasing themselves as not only incredibly accomplished professionals but also as humans with real dynamic lives is what made this course so moving.' — Natnaelle Admassu, MD 'It's great to have more exposure to various ways of doing things and different treatment options. I loved talking with faculty one-on-one at dinner and in small groups on Sunday. Particularly, going through before and after photos and reviewing various filler / toxin / resurfacing options on a case-by-case basis was beneficial.' — Amanda Stallings, DO 'This is hands down the best cosmetic conference I have been to! The lectures provided great evidence-based presentations. I really enjoyed the mentorship and camaraderie. I left the conference feeling confident because I learned so much, and it truly opened my eyes to all of the procedural skills dermatologists can have.' — Autumn Saizan, MD Generous Corporate Support The ASDS Premier Annual Resident Cosmetic Symposium was graciously supported by the following exhibitors and in-kind partners: DiamondGaldermaVichy Laboratoires PlatinumAllergan Aesthetics, an AbbVie Company GoldEvolusMerz SilverAcclaroCandelaCynosureLutronicZO Skin Health BronzeCanfield ScientificComplete DermatologyDermAvanceNutrafolSofwaveTiemann Surgical & Co. Industry representatives interested in branding opportunities and/or on-site exhibiting for the 2026 Symposium can email exhibits@ for more information. # # # About the American Society for Dermatologic Surgery (ASDS)The American Society for Dermatologic Surgery (ASDS) is the largest specialty organization exclusively representing dermatologic surgeons who have the unique training and experience required to treat the health, function and beauty of patients' skin, hair and nails. ASDS members are pioneers in the field, often involved in clinical studies that substantiate popular procedures to revitalize and repair skin, enhance skin care devices and improve standard techniques. Dermatologic surgeons are also experts in skin cancer prevention, detection and treatment. As the incidence of skin cancer rises, dermatologic surgeons are committed to spreading sun safety awareness to minimize the life-threatening effects of this disease. For more information, visit For physician news, follow ASDS Members on Facebook, X (formerly Twitter), Instagram, Threads LinkedIn and patient education, follow ASDS Skin MD on Facebook, X (formerly Twitter), Instagram, Threads, YouTube and a dermatologic surgeon in your area: Attachment 2025 ASDS Resident Symposium in Dallas, Texas CONTACT: Katie Allodi American Society for Dermatologic Surgery 847-956-9143 kallodi@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store